Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything

Cancer Prev Res (Phila). 2009 Mar;2(3):195-6. doi: 10.1158/1940-6207.CAPR-08-0245. Epub 2009 Mar 3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Anticarcinogenic Agents / therapeutic use
  • Atherosclerosis / complications
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / prevention & control*
  • Cardiovascular System / drug effects
  • Cardiovascular System / metabolism
  • Clinical Trials as Topic
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Humans
  • Neoplasms / prevention & control
  • Prostaglandin Antagonists / therapeutic use*
  • Prostaglandins / metabolism*
  • Risk

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticarcinogenic Agents
  • Cyclooxygenase 2 Inhibitors
  • Prostaglandin Antagonists
  • Prostaglandins